Randomised phase 2 study of sapanisertib (TAK228/MLN0128) TAK-117 versus everolimus in patients with VEGF-targeted therapy-refractory metastatic clear cell renal cell carcinoma
Toni K. Choueiri MD of Dana Farber discusses Randomised phase 2 study of sapanisertib (TAK228/MLN0128) TAK-117 versus everolimus in patients with VEGF-targeted therapy-refractory metastatic clear c...
Author: superboy
Added: 04/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - April 1, 2019 Category: Cancer & Oncology Source Type: podcasts
Cell-free tumour DNA (cfDNA) detection in advanced renal cell carcinoma
Samra Turajlic, MD The Royal Marsden NHS Foundation Trust outlines Cell-free tumour DNA (cfDNA) detection in advanced renal cell carcinoma at the Kidney Cancer Association International Symposium 2019...
Author: kidneycancer
Added: 03/30/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 30, 2019 Category: Cancer & Oncology Source Type: podcasts
David F. McDermott, MD - Making Effective Therapeutic Choices for Advanced RCC in an Evolving Treatment Landscape: Personal Insights From the Patient CaseBook
Go online to PeerView.com/FEJ860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Genitourinary Cancers Symposium in San Francisco, experts in renal cell carcinoma (RCC) dip into their patient “CaseBook” to offer insights from their own practice on how best to bridge the divide between clinical research and daily care in the management of RCC. Pairing analysis of the latest evidence with application of key clinical concepts to decision-making in a complex therapeutic landscape, the expert panel explores how best to leverage the potency of newer agents across di...
Source: PeerView CME/CE Audio Podcast - Oncology - March 27, 2019 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
KEYNOTE 426 Phase III Trial In Metastatic Renal Cell Carcinoma
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, Discusses KEYNOTE 42...
Author: obr
Added: 03/20/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2019 Category: Cancer & Oncology Source Type: podcasts
Immunotherapy Biomarkers and Patient Selection [360p]
Dr. Julie Brahmer, Johns Hopkins University, discusses the use of biomarker testing and mutational burden to select patients for specific immunotherapies in lung cancer, renal cell carcinoma and melan...
Author: cancergrace
Added: 03/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 15, 2019 Category: Cancer & Oncology Source Type: podcasts
Sequencing TKIs In Hepatocellular Carcinoma (HCC)
Nevena Damjanov, MD, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania discusses, Sequencing TKIs In Hepatocellular Carcinoma (HCC). At The 2019 Gastrointes...
Author: obr
Added: 02/04/2019 (Source: Oncology Tube)
Source: Oncology Tube - February 4, 2019 Category: Cancer & Oncology Source Type: podcasts
The Utilization Of TKIs In Treatment Of Hepatocellular Carcinoma
Rachna Shroff, MD Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, discusses The Utilization Of TKIs In Tre...
Author: obr
Added: 01/29/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 29, 2019 Category: Cancer & Oncology Source Type: podcasts
How We Can Utilize TKIs In The Management Of Hepatocellular Carcinoma
Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, discusses How We Can Utilize TKIs In The...
Author: obr
Added: 01/29/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 29, 2019 Category: Cancer & Oncology Source Type: podcasts
Jorge A. Marrero, MD, MS - Surveying the View From the Driver ’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes
Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes (Source: PeerView CME/CE Audio Podcast - Oncology)
Source: PeerView CME/CE Audio Podcast - Oncology - January 11, 2019 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
Jorge A. Marrero, MD, MS - Surveying the View From the Driver ’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes
Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes (Source: PeerView CME/CE Audio Podcast - Immunology)
Source: PeerView CME/CE Audio Podcast - Immunology - January 11, 2019 Category: Allergy & Immunology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
Novick Memorial Lecture Heterogeneity of Renal Cell Carcinoma: Lessons learned from biopsy and active surveillance of small renal masses (SRM)
Michael A.S. Jewett DEPARTMENT OF SURGICAL ONCOLOGY PRINCESS MARGARET CANCER CENTRE DIVISION OF UROLOGY THE UNIVERSITY OF TORONTO discusses Heterogeneity of Renal Cell Carcino...
Author: kidneycancer
Added: 11/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - November 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Ipilimumab plus Nivolumab as Salvage Therapy in Patients with Checkpoint Inhibitor-Refractory Metastatic Renal Cell Carcinoma
Kimberly Allman, MSN, CNP Cleveland Clinic Taussig Cancer Institute discusses Ipilimumab plus Nivolumab as Salvage Therapy in Patients with Checkpoint Inhibitor-Refractory Metastatic...
Author: kidneycancer
Added: 11/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - November 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Second-Line VEGFR TKI Outcomes After First-Line Immune Checkpoint Blockade in Metastatic Renal Cell Carcinoma
Ritesh Kotecha discusses Second-Line VEGFR TKI Outcomes After First-Line Immune Checkpoint Blockade in Metastatic Renal Cell Carcinoma at the Seventeenth International Kidney Cancer Inte...
Author: kidneycancer
Added: 11/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - November 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Phase 1b study (COSMIC-021) of cabozantinib in combination with atezolizumab:Results of the dose-escalation stage in patients with treatment-nave advanced renal cell carcinoma
Neeraj Agarwal Huntsman Cancer Center discusses Phase 1b study (COSMIC-021) of cabozantinib in combination with atezolizumab:Results of the dose-escalation stage in patients with treatment-nave adv...
Author: kidneycancer
Added: 11/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - November 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Whole Body MRI for Detection of Renal Cell Carcinoma Osseous Metastases
Alberto Diaz de Leon M.D. discusses Whole Body MRI for Detection of Renal Cell Carcinoma Osseous Metastases at the Seventeenth International Kidney Cancer International Symposium 2018 in...
Author: kidneycancer
Added: 11/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - November 6, 2018 Category: Cancer & Oncology Source Type: podcasts
